Analysis Ascelia Pharma: Phase III with Mangoral

Ascelia Pharma have included the first patient in their pivotal study SPARKLE with the contrast agent Mangoral. This leads to us increasing the probability of a successful outcome of the study and we raise  out target price to SEK 41,9 (previously 34,8).

Read the full report here.